AEE788 is primarily used in cancer research due to its ability to inhibit key signaling pathways involved in tumor growth and progression. It acts as a dual inhibitor of EGFR (epidermal growth factor receptor) and VEGFR (vascular endothelial growth factor receptor), making it effective in blocking both tumor cell proliferation and the formation of new blood vessels that supply tumors. This compound has shown activity in preclinical models of various cancers, including non-small cell lung cancer and glioblastoma. By targeting tyrosine kinases, AEE788 interferes with downstream signaling pathways such as PI3K/AKT and MAPK, which are crucial for cell survival and growth. Due to its potent anti-angiogenic and antiproliferative effects, AEE788 has been used as a tool compound in pharmacological studies to understand kinase inhibitor efficacy and resistance mechanisms. Although it has not advanced to clinical use, it remains valuable in experimental oncology for evaluating combination therapies and novel treatment strategies.